Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral ... Seite 1

Related Keywords

United States , San Francisco , California , American , Himisha Beltran , Drug Administration , Nasdaq , Md Dana Farber Cancer Institute , Harpoon Therapeutics Inc , Harpoon Therapeutics Abstract , Rapid Oral Presentation , Clinical Oncology Genitourinary Cancers Symposium , American Society , Activating Construct , T Cell Engager , Neuroendocrine Prostate Cancer , Neuroendocrine Neoplasms , Rapid Oral Abstract Session , Prostate Cancer , Dana Farber Cancer Institute , Orphan Drug Designation , Harpoon Therapeutics ,